"Health" warns of a way to beautify breasts and that drugs lead to death

The Ministry of Health and Community Protection has warned against the use of a group of antibiotic drugs called FLioroquinolone because of the risk of death, while withdrawing and suspending the commercialization of the medical means used to enlarge and sublimate the breast for technical reasons, as well as the use of test strips for the level of warfarin in the blood.

In a statement issued by the US Food and Drug Administration (FDA), the FDA issued a circular warning against the use of the group of antibiotics FLioroquinolone, likely to cause rare and dangerous lesions , such as rupture of the main artery or blood vessels. .

She confirmed in the circular that the above symptoms only occur with the "FLioroquinolone" group taken orally or by injection, including "levofloxacin-ciprofloxacin-moxifloxacin-ofloxacin-gemifloxin".

In its circular, the Ministry recommended to health practitioners not to prescribe antibiotics to the product intended for patients with arterial conditions such as atherosclerosis and hypertension, as well as some genetic cases such as Marfan syndrome.

(Ehlers-Danlos).

In the circular, she stressed the need to advise all patients to seek prompt treatment of symptoms associated with the expansion of aortic blood vessels.

The Ministry has called on FLioroquinolone-treated patients to seek medical attention immediately when they experience sudden, intense, persistent pain in the stomach, chest, or back, before initiating antibiotic therapy. If they suffer from diseases of the blood vessels and do not stop taking the antibiotic without checking your health professional.

The ministry said in another circular that it had withdrawn and suspended the marketing of medical devices manufactured by the manufacturer (Allergank), used for purposes of breast enlargement and embellishment for reasons techniques.

The European Medicines Agency, in cooperation with the manufacturer, has suspended the marketing of these medical devices in Europe and has suspended the marketing of these medical devices in Europe, confirming that there was currently no evidence of increased risk for patients who used these means and that it was not necessary to remove them. Any additional clinical follow-up.

In a third circular, the ministry warned against the use of Coagucchek XS PT test strips in the blood of warfarin, produced by Roche Diabetes, on the recommendation of the US Food and Drug Administration.